AstraZeneca PLC (AZN)vsenVVeno Medical Corp (NVNO)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
NVNO
enVVeno Medical Corp
$10.50
+0.57%
HEALTHCARE · Cap: $7.81M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
NVNO
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for NVNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : NVNO
The strongest argument for NVNO centers on Price/Book.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : NVNO
The primary concerns for NVNO are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVNO carries more volatility with a beta of 1.09 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 29/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
enVVeno Medical Corp
HEALTHCARE · MEDICAL DEVICES · USA
enVVeno Medical Corp is an innovative medical device company dedicated to transforming vascular access solutions for dialysis patients through its proprietary biocompatible technology. By addressing critical unmet needs in the dialysis sector, enVVeno enhances the safety and efficacy of vascular procedures, allowing it to capitalize on the growing vascular interventions market. The company's commitment to advanced engineering, coupled with stringent regulatory compliance, aligns it with the evolving healthcare landscape and reinforces its mission to improve patient outcomes in a vital area of medical care.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?